BioMed X launches Harvard pilot to connect academia and pharma
Projects selected for advancement will move forward through the Harvard Office of Technology Development’s processes for sponsored research agreements
Projects selected for advancement will move forward through the Harvard Office of Technology Development’s processes for sponsored research agreements
Gefion, powered entirely by renewable energy, boasts more than 1,500 NVIDIA GPUs
Dr. Reddy’s Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% is an antihistamine eye drop, indicated for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair and dander
This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo to patients in France, Denmark, Iceland, Sweden, Finland and Norway
Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding
The grant will fund ten new J.MD projects over the next three years, targeting multiple global health threats
The agreement, signed in December 2025, grants Takeda an exclusive worldwide license to use Halozyme’s proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) with vedolizumab
DME is among the most challenging retinal diseases to treat and has long served as a proving ground for therapies that ultimately become first-line standard of care in retinal diseases
The partnership aims to develop a first-in-class broad-spectrum antifungal to combat life-threatening invasive infections
Subscribe To Our Newsletter & Stay Updated